A detailed history of Jim Simons (Renaissance Technologies LLC) transactions in Immunocore Holdings PLC stock. As of the latest transaction made, Renaissance Technologies LLC holds 276,200 shares of IMCR stock, worth $8.73 Million. This represents 0.01% of its overall portfolio holdings.

Number of Shares
276,200
Previous 646,920 57.31%
Holding current value
$8.73 Million
Previous $21.9 Million 60.78%
% of portfolio
0.01%
Previous 0.04%

Shares

11 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 13, 2024

SELL
$30.06 - $41.49 $11.1 Million - $15.4 Million
-370,720 Reduced 57.31%
276,200 $8.6 Million
Q2 2024

Aug 09, 2024

BUY
$33.78 - $63.75 $2.77 Million - $5.24 Million
82,120 Added 14.54%
646,920 $21.9 Million
Q1 2024

May 13, 2024

BUY
$60.14 - $75.36 $13.2 Million - $16.6 Million
219,700 Added 63.66%
564,800 $36.7 Million
Q4 2023

Feb 13, 2024

SELL
$42.85 - $69.5 $4.76 Million - $7.73 Million
-111,200 Reduced 24.37%
345,100 $23.6 Million
Q3 2023

Nov 14, 2023

BUY
$49.5 - $66.6 $445,500 - $599,400
9,000 Added 2.01%
456,300 $23.7 Million
Q2 2023

Aug 11, 2023

BUY
$48.54 - $61.64 $131,058 - $166,428
2,700 Added 0.61%
447,300 $26.8 Million
Q1 2023

May 12, 2023

BUY
$46.12 - $65.71 $6.43 Million - $9.17 Million
139,500 Added 45.72%
444,600 $22 Million
Q4 2022

Feb 13, 2023

BUY
$45.51 - $65.08 $9.57 Million - $13.7 Million
210,300 Added 221.84%
305,100 $17.4 Million
Q3 2022

Nov 14, 2022

BUY
$37.34 - $57.44 $1.64 Million - $2.52 Million
43,900 Added 86.25%
94,800 $4.45 Million
Q2 2022

Aug 12, 2022

BUY
$25.46 - $37.72 $1.11 Million - $1.64 Million
43,600 Added 597.26%
50,900 $1.9 Million
Q1 2022

May 13, 2022

BUY
$18.94 - $34.29 $138,262 - $250,317
7,300 New
7,300 $218,000

Others Institutions Holding IMCR

About Immunocore Holdings plc


  • Ticker IMCR
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 43,897,100
  • Market Cap $1.39B
  • Description
  • Immunocore Holdings plc, a commercial-stage biotechnology company, engages in the development of immunotherapies for the treatment of cancer, infectious, and autoimmune diseases. The company offers KIMMTRAK for the treatment of patients with unresectable or metastatic uveal melanoma. Its other programs for oncology comprise IMC-C103C that is in ...
More about IMCR
Track Jim Simons's Portfolio

Track Jim Simons Portfolio

Follow Jim Simons (Renaissance Technologies LLC) and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Renaissance Technologies LLC, based on Form 13F filings with the SEC.

News

Stay updated on Renaissance Technologies LLC and Jim Simons with notifications on news.